Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Biliary Tract Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer

Interventions

DRUG: TU2218 + KEYTRUDA® (Pembrolizumab)

Sponsor

TiumBio Co., Ltd.

Collaborators

[object Object]